問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Cardiovascular Diseases

Division of General Surgery

Division of Radiation Therapy

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

劉峻宇Liu, Chun-Yu
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

88Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉峻宇

List

171Cases

2012-12-03 - 2018-09-05

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2012-11-01 - 2018-01-31

Phase III

A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as Hormonal Treatment for Postmenopausal Women with Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy (FALCON)

  • Condition/Disease

    Breast Cancer

  • Test Drug

    FASLODEX

Participate Sites
5Sites

Terminated5Sites

2012-06-01 - 2013-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2020-11-20 - 2025-12-31

Phase I

A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08)

  • Condition/Disease

    Metastatic HER2-low Breast Cancer

  • Test Drug

    Trastuzumab deruxtecan (ENHERTUR) Durvalumab (Imfinzi?) Capivasertib

Participate Sites
7Sites

Recruiting7Sites

2020-10-15 - 2027-09-01

Phase III

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy (DESTINY-Breast05)

  • Condition/Disease

    HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast

  • Test Drug

    Trastuzumab deruxtecan (T-DXd; DS-8201a)

Participate Sites
13Sites

Recruiting13Sites

2017-02-01 - 2027-02-01

Phase III

PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

  • Condition/Disease

    Hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

  • Test Drug

    Ibrance

Participate Sites
6Sites

Terminated5Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

侯明鋒
Kaohsiung Municipal Gangshan Hospital

未分科

2015-01-15 - 2023-06-06

Phase III

A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer.

  • Condition/Disease

    hormone receptor positive, HER2-negative, advanced breast cancer.

  • Test Drug

    LEE011

Participate Sites
8Sites

Terminated8Sites

2015-10-01 - 2020-04-30

Phase III

SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor (AI) treatment

  • Condition/Disease

    hormone receptor positive, HER2-negative advanced breast cancer

  • Test Drug

    BYL719/Faslodex

Participate Sites
3Sites

Terminated3Sites

曾令民
Taipei Veterans General Hospital

2014-02-01 - 2016-05-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2011-05-15 - 2013-11-15

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 13 14 15 16 17 18
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB